The company is well poised to enable local development and manufacturing in India to drive affordable and accessible CGTs by academia and industry for Indian as well as global patients. In conversation with BioSpectrum Asia, Dr Boris Stoffel, Chief Executive Officer and Managing Director of Miltenyi Biotec, talks about the real challenges associated with the use of CGT, and the way forward.
Could you elaborate on the narrative behind Miltenyi Biotec’s invention of the groundbreaking technology that has led to the development of new procedures for treating diseases through Cell and Gene Therapy? How was this achieved?
Miltenyi Biotec, being a private entity, stands as the pioneer in next-generation technology within the field of Cell and Gene Therapy (CGT). The significance of this technology persists even after 35 years, as it emerged in 1989 at a time when the concept of disruptive technology was still nascent. Looking back 35 years, it's evident that our innovation was disruptive because, at that time, only a handful of labs worldwide utilised large-scale cell sorters. Specialised operators were required to sort immune cells from blood, making it a cumbersome process.
The invention of MACS technology revolutionised this landscape by enabling every researcher to utilise a simple column and antibodies coupled with small microbeads in a magnetic field to separate cells within a short timeframe. This democratisation of technology meant that researchers were no longer reliant on expensive, specialised equipment available only in select labs. At that time, Germany, for instance, had only two such sorters, one of which was located at the Institute of Genetics of Immunology, where Stefan Miltenyi, the founder, was a student.
ãã®èšäºã¯ BioSpectrum Asia ã® BioSpectrum Asia April 2024 çã«æ²èŒãããŠããŸãã
7 æ¥éã® Magzter GOLD ç¡æãã©ã€ã¢ã«ãéå§ããŠãäœåãã®å³éžããããã¬ãã¢ã ã¹ããŒãªãŒã8,500 以äžã®éèªãæ°èã«ã¢ã¯ã»ã¹ããŠãã ããã
ãã§ã«è³Œèªè ã§ã ?  ãµã€ã³ã€ã³
ãã®èšäºã¯ BioSpectrum Asia ã® BioSpectrum Asia April 2024 çã«æ²èŒãããŠããŸãã
7 æ¥éã® Magzter GOLD ç¡æãã©ã€ã¢ã«ãéå§ããŠãäœåãã®å³éžããããã¬ãã¢ã ã¹ããŒãªãŒã8,500 以äžã®éèªãæ°èã«ã¢ã¯ã»ã¹ããŠãã ããã
ãã§ã«è³Œèªè ã§ã? ãµã€ã³ã€ã³
Australia invests $1.89B for health and medical research transformation
The government is investing in a once in a generation transformation of health and medical research in Australia.
NZ suggests new way to prevent rheumatic heart disease progression
A new way of delivering treatment to prevent rheumatic heart disease progression is significantly less painful than an almost 70-year-old existing treatment, a University of Otago-led study in New Zealand (NZ) has found.
WHO prequalifies Takeda's dengue vaccine
A new vaccine for dengue has received prequalification from the World Health Organization (WHO).
GIBF invests $10M in Israel's Nectin Therapeutics to advance ADCs
Guangzhou-Israel Biotechnology Fund (GIBF) has invested $10 million in Nectin Therapeutics.
HOYA Group to distribute AIassisted lesion detection device in US
Japan-based HOYA Group Company, PENTAX of America, Inc. (PENTAX Medical, a division of HOYA Group) and MAGENTIQ-EYE, an artificial intelligence (AI)-based medical device company, have announced their intention to form a partnership in the field of AI in gastroenterology and to examine further collaboration and strategic partnerships.
Saudi Arabia pledges $500M to protect children from polio
At the first-ever World Economic Forum (WEF) Special Meeting hosted in Riyadh recently, the Kingdom of Saudi Arabia has pledged $500 million over the next five years to support the work of the Global Polio Eradication Initiative (GPEI).
Scientists explore use of COVID-19 variant vaccine against other coronaviruses
An international consortium of researchers developing a vaccine against troublesome COVID-19 variants will receive additional CEPI funding to investigate whether it could also protect against other deadly coronaviruses.
How Thai Biotech is Thriving with Innovations
Thailand's biotech industry is rapidly evolving, positioning itself as a key player in the ASEAN regions and the global biotechnology landscape. With a strategic focus on research and development, supportive government policies and a burgeoning ecosystem of startups and research institutions, Thailand is emerging as a hotspot for biotech innovation in Southeast Asia.
Why multi-use real estate is in demand for life sciences companies
India's Biocon, Enzene Biosciences, and Meteoric Biopharmacueticals, Japan's Daiichi Sankyo, and Singapore's Hummingbird Bioscience, have all recently sought to lease, acquire, and set up shop in a mixed-use space in the US. And for those companies who wish to enter or expand in the US market, New Jersey is a top choice due to its existing infrastructure, cultural connections, robust talent and location.
"The dialogue surrounding pharmaceutical gowning is experiencing significant transformation in 2024 & beyond"
Finland-based Lindström, a leading global provider of workwear, cleanroom workwear, and mat services, is making significant strides in its expansion efforts, particularly in key markets such as India, China, Vietnam, and Turkey.